東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Analysis file of drug-induced lung i...

Gemma, Akihiko.

FindBook

Google Book

Amazon

博客來

Analysis file of drug-induced lung injury = expert opinion for analysis of big data /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Analysis file of drug-induced lung injury/ by Akihiko Gemma.
其他題名:	expert opinion for analysis of big data /
作者:	Gemma, Akihiko.
出版者:	Singapore :Springer Nature Singapore : : 2024.,
面頁冊數:	xii, 116 p. :ill. (some col.), digital ;24 cm.
內容註:	Part I Understanding Drug-Induced Lung Injuries -- 1 Understanding Drug-Induced Lung Injuries -- Part 2 Actual Practice in Drug-Induced Lung Injuries of Each Drug -- 2 EGFR inhibitors (gefitinib, erlotinib, afatinib, osimertinib) -- 3 Anti-EGFR antibodies (cetuximab, panitumumab, necitumumab) -- 4 mTOR inhibitors (temsirolimus, everolimus) -- 5 Proteasome inhibitor (bortezomib) -- 6 Immune checkpoint inhibitors (nivolumab, pembrolizumab, atezolizumab, durvalumab) -- 7 Neoangiogenesis inhibitors (sunitinib, sorafenib, bevacizumab) -- 8 Other molecular targeted drugs (crizotinib, alectinib, etc.) -- 9 Antibody-drug conjugates (ADC) (trastuzumab emtansine, trastuzumab deruxtecan) -- 10 Anti-cancer drugs (TS-1, taxanes, CPT-11, platinum-containing drugs, etc.)
Contained By:	Springer Nature eBook
標題:	Lungs - Wounds and injuries. -
電子資源:	https://doi.org/10.1007/978-981-97-3446-7
ISBN:	9789819734467

Analysis file of drug-induced lung injury = expert opinion for analysis of big data /
Gemma, Akihiko.

Analysis file of drug-induced lung injuryexpert opinion for analysis of big data /[electronic resource] :by Akihiko Gemma. - Singapore :Springer Nature Singapore :2024. - xii, 116 p. :ill. (some col.), digital ;24 cm.

Part I Understanding Drug-Induced Lung Injuries -- 1 Understanding Drug-Induced Lung Injuries -- Part 2 Actual Practice in Drug-Induced Lung Injuries of Each Drug -- 2 EGFR inhibitors (gefitinib, erlotinib, afatinib, osimertinib) -- 3 Anti-EGFR antibodies (cetuximab, panitumumab, necitumumab) -- 4 mTOR inhibitors (temsirolimus, everolimus) -- 5 Proteasome inhibitor (bortezomib) -- 6 Immune checkpoint inhibitors (nivolumab, pembrolizumab, atezolizumab, durvalumab) -- 7 Neoangiogenesis inhibitors (sunitinib, sorafenib, bevacizumab) -- 8 Other molecular targeted drugs (crizotinib, alectinib, etc.) -- 9 Antibody-drug conjugates (ADC) (trastuzumab emtansine, trastuzumab deruxtecan) -- 10 Anti-cancer drugs (TS-1, taxanes, CPT-11, platinum-containing drugs, etc.)

This book describes the pathologic conditions of drug-induced lung injuries, monitoring strategies, and guides on how to interpret the evidence. It also dives into particular drugs that caused the disorder, such as EGFR inhibitors, anti-EGFR antibodies, mTOR inhibitors, proteasome inhibitors, immune checkpoint inhibitors, neoangiogenesis inhibitors, and other molecular targeted drugs. It outlines the analysis and interpretation of the post-marketing survey on surveillance of each drug for inducing pulmonary lesions presenting diffuse haziness. The data and analysis from this survey are valuable since a guideline is yet to be established due to limited clinical evidence and cases. As new drugs are developed, establishing treatment and event management is crucial. Thus, Drug-induced Pulmonary Disorder in Medical Oncology - Expert Opinion to Decipher Big Data summarizes the accumulated information to provide a foundation for further research advancement. The book offers a refreshing alternative to current approaches to medical oncology and respiratory diseases professionals and will also attract medical affairs members in global pharmaceutical companies.

ISBN: 9789819734467

Standard No.: 10.1007/978-981-97-3446-7doiSubjects--Topical Terms:

1530553
Lungs
--Wounds and injuries.

LC Class. No.: RC756

Dewey Class. No.: 616.24

Analysis file of drug-induced lung injury = expert opinion for analysis of big data /
LDR:02936nmm a2200325 a 4500 001 2374496
003 DE-He213
005 20240802130230.0
006 m d
007 cr nn 008maaau
008 241231s2024 si s 0 eng d
020 $a 9789819734467 $q (electronic bk.)
020 $a 9789819734450 $q (paper)
024 7 $a 10.1007/978-981-97-3446-7 $2 doi
035 $a 978-981-97-3446-7
040 $a GP $c GP
041 1 $a eng $h jpn
050 4 $a RC756
072 7 $a MJL $2 bicssc
072 7 $a MED079000 $2 bisacsh
072 7 $a MJL $2 thema
082 0 4 $a 616.24 $2 23
090 $a RC756 $b .G323 2024
100 1 $a Gemma, Akihiko. $3 3723400
245 1 0 $a Analysis file of drug-induced lung injury $h [electronic resource] : $b expert opinion for analysis of big data / $c by Akihiko Gemma.
260 $a Singapore : $b Springer Nature Singapore : $b Imprint: Springer, $c 2024.
300 $a xii, 116 p. : $b ill. (some col.), digital ; $c 24 cm.
505 0 $a Part I Understanding Drug-Induced Lung Injuries -- 1 Understanding Drug-Induced Lung Injuries -- Part 2 Actual Practice in Drug-Induced Lung Injuries of Each Drug -- 2 EGFR inhibitors (gefitinib, erlotinib, afatinib, osimertinib) -- 3 Anti-EGFR antibodies (cetuximab, panitumumab, necitumumab) -- 4 mTOR inhibitors (temsirolimus, everolimus) -- 5 Proteasome inhibitor (bortezomib) -- 6 Immune checkpoint inhibitors (nivolumab, pembrolizumab, atezolizumab, durvalumab) -- 7 Neoangiogenesis inhibitors (sunitinib, sorafenib, bevacizumab) -- 8 Other molecular targeted drugs (crizotinib, alectinib, etc.) -- 9 Antibody-drug conjugates (ADC) (trastuzumab emtansine, trastuzumab deruxtecan) -- 10 Anti-cancer drugs (TS-1, taxanes, CPT-11, platinum-containing drugs, etc.)
520 $a This book describes the pathologic conditions of drug-induced lung injuries, monitoring strategies, and guides on how to interpret the evidence. It also dives into particular drugs that caused the disorder, such as EGFR inhibitors, anti-EGFR antibodies, mTOR inhibitors, proteasome inhibitors, immune checkpoint inhibitors, neoangiogenesis inhibitors, and other molecular targeted drugs. It outlines the analysis and interpretation of the post-marketing survey on surveillance of each drug for inducing pulmonary lesions presenting diffuse haziness. The data and analysis from this survey are valuable since a guideline is yet to be established due to limited clinical evidence and cases. As new drugs are developed, establishing treatment and event management is crucial. Thus, Drug-induced Pulmonary Disorder in Medical Oncology - Expert Opinion to Decipher Big Data summarizes the accumulated information to provide a foundation for further research advancement. The book offers a refreshing alternative to current approaches to medical oncology and respiratory diseases professionals and will also attract medical affairs members in global pharmaceutical companies.
650 0 $a Lungs $x Wounds and injuries. $3 1530553
650 0 $a Lungs $x Diseases. $3 1006034
650 0 $a Drugs $x Side effects. $3 789547
650 1 4 $a Pneumology. $3 3596538
650 2 4 $a Clinical Genetics. $3 3601333
650 2 4 $a Pathogenesis. $3 3561735
650 2 4 $a Oncology. $3 751006
650 2 4 $a Pharmacology. $3 634543
650 2 4 $a Genetics Research. $3 3627741
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-981-97-3446-7
950 $a Medicine (SpringerNature-11650)